GRAMD1B and opportunistic mycosis: LAmB is the recommended induction therapy for several common endemic mycoses including blastomycosis and histoplasmosis, though clinical trials evaluating LAmB in endemic mycoses are limited.51 One seminal double-blind, multicentre, randomized clinical trial compared the safety and efficacy of LAmB (3.0 mg/kg/d) versus DAmB (0.7 mg/kg/d) for 14 days in 81 patients with AIDS and disseminated histoplasmosis.101 Clinical success was achieved in a greater percentage of LAmB-treated patients (88%) compared with DAmB-treated patients (64%; P = 0.014).